{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:10:58Z","timestamp":1782547858346,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81830115"],"award-info":[{"award-number":["81830115"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Diarrhea-predominant irritable bowel syndrome (IBS-D) is a bowel disease with a high incidence. It significantly reduces the quality of life of patients and affects the patient's daily activities and mental health. No specific therapeutic medications for IBS-D have been found. Published clinical trials suggest that Chinese herbal formula Tongxie Yaofang (TXYF) for IBS-D may be effective. However, high-quality clinical evidence supporting its use in IBS-D is still lacking. This trial aims to evaluate the therapeutic effects and safety of TXYF for IBS-D in adults.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>A randomized, multiple-blind, placebo-controlled trial will be conducted. It will consist of an 8-week intervention followed by a 3-month follow-up period.<\/jats:p>\n                <jats:p>The target sample size is 96 IBS-D patients aged 18 to 65\u2009years. The eligible participants will be randomly allocated to either TXYF or placebo group in a ratio of 1:1. Participants in the experimental group will take TXYF granules, while participants in the control group will be given TXYF placebo granules. The primary outcome will be the degree of IBS symptom severity measured using the scale of IBS symptom severity score. The secondary outcomes include: (a) stool frequency, and (b) stool consistency measured using the Bristol stool scale, (c) quality of life measured using the scale of IBS-quality of life, (d) anxiety measured using the self-rating anxiety scale, (e) depression measured by the self-rating depression scale, and (f) the safety of using TXYF and placebo. Safety monitoring and assessment will be undertaken throughout treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Chinese herbal formula TXYF consists of four Chinese herbs: <jats:italic>Atractylodes macrocephala Koidz.<\/jats:italic>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/mpns.science.kew.org\/mpns-portal\/plantDetail?plantId=519125&amp;query=Bai+Shao&amp;filter=&amp;fuzzy=false&amp;nameType=all&amp;dbs=wcs\"><jats:italic>Paeonia lactiflora Pall<\/jats:italic><\/jats:ext-link><jats:italic>.<\/jats:italic>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/mpns.science.kew.org\/mpns-portal\/plantDetail?plantId=723957&amp;query=Chen+Pi&amp;filter=&amp;fuzzy=false&amp;nameType=all&amp;dbs=wcsCmp\"><jats:italic>Citrus \u00d7 aurantium L<\/jats:italic><\/jats:ext-link><jats:italic>.<\/jats:italic>, and <jats:italic>Radix saposhnikoviae<\/jats:italic>. It has been used for diarrhea for hundreds of years and may have a potential benefit in treating adults with IBS-D, but due to lack of high-quality evidence, we designed a randomized, multiple-blind, placebo-controlled trial to evaluate its therapeutic effects and safety. This trial will provide important data to guide the clinical practice of TXYF for the treatment of IBS-D in adults.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ISRCTN registry <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1186\/ISRCTN12453166\">ISRCTN12453166<\/jats:ext-link>. Registered on 23 March 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06142-x","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T10:02:33Z","timestamp":1647856953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized, multiple-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Shi-Bing","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Jie","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Yi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"issue":"7","key":"6142_CR1","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","volume":"10","author":"RM Lovell","year":"2012","unstructured":"Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712\u2013721.e4. https:\/\/doi.org\/10.1016\/j.cgh.2012.02.029.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"6142_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.pop.2017.07.009","volume":"44","author":"DN Defrees","year":"2017","unstructured":"Defrees DN, Bailey J. Irritable bowel syndrome: epidemiology, pathophysiology, diagnosis, and treatment. Prim Care. 2017;44(4):655\u201371. https:\/\/doi.org\/10.1016\/j.pop.2017.07.009.","journal-title":"Prim Care"},{"issue":"11","key":"6142_CR3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","volume":"21","author":"AP Hungin","year":"2005","unstructured":"Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21(11):1365\u201375. https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02463.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"6142_CR4","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/ajg.2014.187","volume":"109","author":"AC Ford","year":"2014","unstructured":"Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2\u201326; quiz S27. https:\/\/doi.org\/10.1038\/ajg.2014.187.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"6142_CR5","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1111\/j.1572-0241.2008.02048.x","volume":"103","author":"YA Saito","year":"2008","unstructured":"Saito YA, Talley NJ. Genetics of irritable bowel syndrome. Am J Gastroenterol. 2008;103(8):2100\u20135. https:\/\/doi.org\/10.1111\/j.1572-0241.2008.02048.x.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"6142_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1572-0241.2007.01722.x","volume":"103","author":"DK Chitkara","year":"2008","unstructured":"Chitkara DK, van Tilburg MA, Blois-Martin N, Whitehead WE. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol. 2008;103(3):765\u201374; quiz 775. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01722.x.","journal-title":"Am J Gastroenterol"},{"key":"6142_CR7","doi-asserted-by":"publisher","first-page":"291452","DOI":"10.1155\/2012\/291452","volume":"2012","author":"AS Butt","year":"2012","unstructured":"Butt AS, Salih M, Jafri W, Yakoob J, Wasay M, Hamid S. Irritable bowel syndrome and psychiatric disorders in pakistan: a case control study. Gastroenterol Res Pract. 2012;2012:291452. https:\/\/doi.org\/10.1155\/2012\/291452.","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"6142_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1572-0241.2002.05428.x","volume":"97","author":"PR Maxwell","year":"2002","unstructured":"Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol. 2002;97(1):104\u20138. https:\/\/doi.org\/10.1111\/j.1572-0241.2002.05428.x.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"6142_CR9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","volume":"150","author":"F Mearin","year":"2016","unstructured":"Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterol. 2016;150(6):1393\u20131407.e5. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.031.","journal-title":"Gastroenterol."},{"issue":"10","key":"6142_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","volume":"5","author":"P Oka","year":"2020","unstructured":"Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(20)30217-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"27","key":"6142_CR11","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.3748\/wjg.v20.i27.8807","volume":"20","author":"M Bellini","year":"2014","unstructured":"Bellini M, Gambaccini D, Stasi C, Urbano MT, Marchi S, Usai-Satta P. Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol. 2014;20(27):8807\u201320. https:\/\/doi.org\/10.3748\/wjg.v20.i27.8807.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"6142_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.4103\/0366-6999.201597","volume":"130","author":"XL Wang","year":"2017","unstructured":"Wang XL, Zhou JN, Ren L, Pan XL, Ren HY, Liu J. Improvement of quality of nonanesthetic colonoscopy by preoperative administration of pinaverium bromide. Chin Med J. 2017;130(6):631\u20135. https:\/\/doi.org\/10.4103\/0366-6999.201597.","journal-title":"Chin Med J"},{"issue":"7536","key":"6142_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1136\/bmj.332.7536.280","volume":"332","author":"A Agrawal","year":"2006","unstructured":"Agrawal A, Whorwell PJ. Irritable bowel syndrome: diagnosis and management. BMJ. 2006;332(7536):280\u20133. https:\/\/doi.org\/10.1136\/bmj.332.7536.280.","journal-title":"BMJ."},{"issue":"4","key":"6142_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3969\/j.issn.1003-8914.2016.04.074","volume":"31","author":"JB Wang","year":"2016","unstructured":"Wang JB, Xu HX. Clinical study progress of therapy of TCM in the treatment of diarrhea-predominant irritable bowel syndrome. Guangming J Chin Med. 2016;31(4):599\u2013602. https:\/\/doi.org\/10.3969\/j.issn.1003-8914.2016.04.074.","journal-title":"Guangming J Chin Med"},{"issue":"11","key":"6142_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3969\/j.issn.1006-0979.2015.11.143","volume":"34","author":"DJ Diao","year":"2015","unstructured":"Diao DJ. General Situation of TCM Treatment of diarrhea-predominant irritable bowel syndrome. J Neimenggu Chin herbal med. 2015;34(11):154\u20135. https:\/\/doi.org\/10.3969\/j.issn.1006-0979.2015.11.143.","journal-title":"J Neimenggu Chin herbal med"},{"issue":"08","key":"6142_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.16305\/j.1007-1334.2017.08.021","volume":"51","author":"QM Dai","year":"2017","unstructured":"Dai QM, Chen XX, Li K, Yin Y, Zhang JY, Wang JW. Discussion on prescription origin of Tongxie Yao Fang and the syndrome corresponding to prescription. Shanghai J Tradit Chin Med. 2017;51(08):73\u20136. https:\/\/doi.org\/10.16305\/j.1007-1334.2017.08.021.","journal-title":"Shanghai J Tradit Chin Med"},{"issue":"07","key":"6142_CR17","first-page":"52","volume":"36","author":"T Wei","year":"2020","unstructured":"Wei T, Li YX, Chen J, Zhao SM, Wang ZX, Li HZ, et al. Effect of Tongxie Yaofang on CRH-R1 expression and mast cells of IBS-D rat with liver-depression and spleen-deficiency syndrome. Shanxi Tradit. Chin Med. 2020;36(07):52\u201354+57.","journal-title":"Chin Med"},{"issue":"15","key":"6142_CR18","first-page":"2012","volume":"35","author":"GQ Chao","year":"2010","unstructured":"Chao GQ, Lv B, Meng LN, Zhang S, Zhang L, Guo Y. Influence of Tongxie prescription on CRF expression in spinal cord and brain of hypersensitive viscera rats. China J Chin Mater Med. 2010;35(15):2012\u20136.","journal-title":"China J Chin Mater Med"},{"issue":"8","key":"6142_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3969\/j.issn.1005-9903.2010.08.041","volume":"16","author":"MX Wei","year":"2010","unstructured":"Wei MX, Wu YM, Liu ZQ, Tian L. Effect and mechanisms of composition of tongxie yaofang on in vitro contraction of colonic smooth muscle strips of rat. Chin J Exp Tradit Med Formulae. 2010;16(8):131\u20134. https:\/\/doi.org\/10.3969\/j.issn.1005-9903.2010.08.041.","journal-title":"Chin J Exp Tradit Med Formulae"},{"issue":"10","key":"6142_CR20","first-page":"1","volume":"24","author":"XP Tan","year":"2014","unstructured":"Tan XP, Han ZY, Wen Y, Liu DM, Hu XG. Effects of Tongxie Yaofang and Radix Saposhnikoviae on the barrier functions of human intestinal Caco-2 cell. Shenzhen J Integr Tradit Chin and Western Med. 2014;24(10):1\u20133.","journal-title":"Shenzhen J Integr Tradit Chin and Western Med"},{"issue":"05","key":"6142_CR21","first-page":"731","volume":"37","author":"JZ Liang","year":"2021","unstructured":"Liang JZ. Clinical observation on treating irritable bowel syndrome with modified Tongxie Yaofang. J Prac Tradit Chin Med. 2021;37(05):731\u20132.","journal-title":"J Prac Tradit Chin Med"},{"issue":"19","key":"6142_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.14033\/j.cnki.cfmr.2020.19.019","volume":"18","author":"X Yang","year":"2020","unstructured":"Yang X. The effect of modified Tongxie Yaofang on TCM syndrome and quality of life of diarrhea-predominant irritable bowel syndrome with liver depression and spleen deficiency. Chin Foreign Med Res. 2020;18(19):49\u201351. https:\/\/doi.org\/10.14033\/j.cnki.cfmr.2020.19.019.","journal-title":"Chin Foreign Med Res"},{"issue":"12","key":"6142_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.13422\/j.cnki.syfjx.20201221","volume":"26","author":"SJ Yao","year":"2020","unstructured":"Yao SJ, Wang YR, Zhang MM. Clinical efficacy and mechanism of Tongxie Yaofang on patients with IBS-D of liver depression and spleen deficiency. Chin J Exp Tradit Med Formulae. 2020;26(12):107\u201313. https:\/\/doi.org\/10.13422\/j.cnki.syfjx.20201221.","journal-title":"Chin J Exp Tradit Med Formulae"},{"issue":"14","key":"6142_CR24","first-page":"107","volume":"27","author":"CR Duan","year":"2018","unstructured":"Duan CR, Zhao N. Clinical observation of Tongxie Yaofang in treating diarrhea-predominant irritable bowel syndrome. Chin J Ethnomed and Ethnopharmacy. 2018;27(14):107\u20138.","journal-title":"Chin J Ethnomed and Ethnopharmacy"},{"key":"6142_CR25","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. https:\/\/doi.org\/10.1136\/bmj.e7586.","journal-title":"BMJ."},{"issue":"18","key":"6142_CR26","first-page":"1614","volume":"58","author":"SS Zhang","year":"2017","unstructured":"Zhang SS, Wei WW, Yang JQ. The diagnostic criteria for TCM syndromes (2017). J Chin Med. 2017;58(18):1614\u201320.","journal-title":"J Chin Med"},{"issue":"5","key":"6142_CR27","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1053\/j.gastro.2014.09.001","volume":"147","author":"DS Weinberg","year":"2014","unstructured":"Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S. Amercian Gastroenterological Association. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147(5):1146\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2014.09.001.","journal-title":"Gastroenterology."},{"issue":"10","key":"6142_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3969\/j.issn.1672-2531.2004.10.011","volume":"4","author":"J Li","year":"2004","unstructured":"Li J. Allocation concealment: why and how? Chin J Evid Based Med. 2004;4(10):714\u20135. https:\/\/doi.org\/10.3969\/j.issn.1672-2531.2004.10.011.","journal-title":"Chin J Evid Based Med"},{"key":"6142_CR29","first-page":"94","volume-title":"Clinical epidemiology: clinical research design, measurement and evaluation","author":"JL Wang","year":"2014","unstructured":"Wang JL. Clinical epidemiology: clinical research design, measurement and evaluation. 4th ed. Shanghai: Shanghai Science and Technology Publishers; 2014. p. 94\u20135.","edition":"4"},{"issue":"2","key":"6142_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.eujim.2013.07.011","volume":"6","author":"A Flower","year":"2014","unstructured":"Flower A, Witt C, Liu J, Ulrich-Merzenich G, Muir K, He Y, et al. GP-TCM Unabridged guidelines for randomised controlled trials investigating Chinese herbal medicine (CHM). Eur J Integr Med. 2014;6(2):186\u2013210. https:\/\/doi.org\/10.1016\/j.eujim.2013.07.011.","journal-title":"Eur J Integr Med"},{"key":"6142_CR31","first-page":"536","volume":"07","author":"JP Liu","year":"2003","unstructured":"Liu JP. Calculation of sample size in clinical trials. Chin J Integr Trad West Med. 2003;07:536\u20138.","journal-title":"Chin J Integr Trad West Med"},{"issue":"2","key":"6142_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","volume":"11","author":"CY Francis","year":"1997","unstructured":"Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395\u2013402. https:\/\/doi.org\/10.1046\/j.1365-2036.1997.142318000.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"6142_CR33","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/00365529709011203","volume":"32","author":"SJ Lewis","year":"1997","unstructured":"Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920\u20134. https:\/\/doi.org\/10.3109\/00365529709011203.","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"6142_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1023\/a:1018831127942","volume":"43","author":"DL Patrick","year":"1998","unstructured":"Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43(2):400\u201311. https:\/\/doi.org\/10.1023\/a:1018831127942.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"6142_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/s0033-3182(71)71479-0","volume":"12","author":"WW Zung","year":"1971","unstructured":"Zung WW. A rating instrument for anxiety disorders. Psychosomatics. 1971;12(6):371\u20139. https:\/\/doi.org\/10.1016\/s0033-3182(71)71479-0.","journal-title":"Psychosomatics."},{"key":"6142_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/archpsyc.1965.01720310065008","volume":"12","author":"WW Zung","year":"1965","unstructured":"Zung WW. A self-rating depression scale. Arch Gen Psychiary. 1965;12:63\u201370. https:\/\/doi.org\/10.1001\/archpsyc.1965.01720310065008.","journal-title":"Arch Gen Psychiary"},{"key":"6142_CR37","unstructured":"Tang B. The study on the clinical features of IBS-D and the treatment of liver-depression and spleen-deficiency. Master dissertation. Tianjin U. Chin Med. 2017."},{"issue":"2","key":"6142_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/apt.14817","volume":"48","author":"M Chen","year":"2018","unstructured":"Chen M, Tang TC, Wang Y, Shui J, Xiao XH, Lan X, et al. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(2):160\u20138. https:\/\/doi.org\/10.1111\/apt.14817.","journal-title":"Aliment Pharmacol Ther"},{"key":"6142_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3969\/j.issn.1672-2531.2006.02.004","volume":"02","author":"G Wang","year":"2006","unstructured":"Wang G, Li TQ, Wang L, Xia Q, Chen Y, Zhang RM. Tongxiening granules in the treatment of diarrhea irritable bowel syndrome (Stagnation of the Liver-Qi Attacking the Spleen): a prospective randomized, placebo-controlled, double-blind clinical trial. Chin J Evidence-Based Med. 2006;02:84\u20139. https:\/\/doi.org\/10.3969\/j.issn.1672-2531.2006.02.004.","journal-title":"Chin J Evidence-Based Med"},{"key":"6142_CR40","first-page":"31","volume-title":"Estimation of clinical research sample size","author":"SX Wu","year":"2008","unstructured":"Wu SX, Wang CX. Estimation of clinical research sample size. Beijing: People\u2019s Health Publishing House; 2008. p. 31\u20132."},{"issue":"5","key":"6142_CR41","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.clnu.2017.08.004","volume":"37","author":"P Gorecki","year":"2018","unstructured":"Gorecki P, Burke DL, Chapple ILC, Hemming K, Saund D, Pearson D, et al. Perioperative supplementation with a fruit and vegetable juice powder concentrate and postsurgical morbidity: a double-blind, randomised, placebo-controlled clinical trial. Clin Nutr. 2018;37(5):1448\u201355. https:\/\/doi.org\/10.1016\/j.clnu.2017.08.004.","journal-title":"Clin Nutr"},{"key":"6142_CR42","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/nrdp.2016.14.P","volume":"2","author":"P Enck","year":"2016","unstructured":"Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:16014. https:\/\/doi.org\/10.1038\/nrdp.2016.14.P.","journal-title":"Nat Rev Dis Primers"},{"key":"6142_CR43","unstructured":"Li M. Clinical epidemiological investigation and research on TCM syndromes of irritable bowel syndrome: Master dissertation. Guangzhou U Chin Med; 2012."},{"key":"6142_CR44","doi-asserted-by":"publisher","first-page":"CD004116","DOI":"10.1002\/14651858.CD004116.pub2","volume":"1","author":"JP Liu","year":"2006","unstructured":"Liu JP, Yang M, Liu YX, Wei M, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2006;1:CD004116. https:\/\/doi.org\/10.1002\/14651858.CD004116.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"6142_CR45","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.3748\/wjg.v21.i16.4852","volume":"21","author":"HL Shi","year":"2015","unstructured":"Shi HL, Liu CH, Ding LL, Zheng Y, Fei XY, Lu L, et al. Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction. World J Gastroenterol. 2015;21(16):4852\u201363. https:\/\/doi.org\/10.3748\/wjg.v21.i16.4852.","journal-title":"World J Gastroenterol"},{"key":"6142_CR46","first-page":"1075","volume":"23","author":"XG Hu","year":"2012","unstructured":"Hu XG, Wang ZH. The clinic study of Tongxie Yaofang on stagnation and spleen deficiency in 35 D-IBS patients. Chin Med J. 2012;23:1075\u20139.","journal-title":"Chin Med J"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06142-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T10:09:41Z","timestamp":1647857381000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06142-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6142"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06142-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"22 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial has been approved by the Medical Ethics Committee, Fangshan Hospital of Beijing University of Chinese Medicine, on 4 February 2021, ref: FZY LK-2021-002.The aim and potential risks of this trial will be fully explained to the participants. Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}